Skip to main content

Advertisement

Table 3 Logistic regression model for predicting tumor response

From: FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

  n Logistic regression OR [95% CI] (Pvalue)
Nodal status   
  N0 51 1 (ref)
  N1 80 0.962 [0.446; 2.078] (0.922)
Grading   
  G2–3 110 1 (ref)
  G1 20 1.203 [0.433; 3.339] (0.723)
Baseline tumor size   
  > 2 cm 16 1 (ref)
  ≤ 2 cm 114 0.742 [0.242; 2.274] (0.601)
Age   
  ≥ 65 years 100 1 (ref)
  < 65 years 31 1.189 [0.483; 2.924] (0.707)
Treatment   
  LET 65 1 (ref)
  LET + ZOL 66 1.722 [0.827; 3.586] (0.147)